PF-06445974

• CAT Number: I034488
• CAS Number: 2055776-17-3
• Molecular Formula: C20H15FN4O
• Molecular Weight: 346.36
• Purity: ≥95%
• Synonyms: 4-(11-cyclopropyl-10-oxo-1,6,11-triazatricyclo[7.4.0.02,7]trideca-2(7),3,5,8-tetraen-8-yl)-2-fluorobenzonitrile
• InChI: InChI=1S/C20H15FN4O/c21-15-10-12(3-4-13(15)11-22)17-18-16(2-1-7-23-18)25-9-8-24(14-5-6-14)20(26)19(17)25/h1-4,7,10,14H,5-6,8-9H2
• InChIKey: YWTCDMZVTLNYLN-UHFFFAOYSA-N
• SMILES: C1CC1N2CCN3C4=C(C(=C3C2=O)C5=CC(=C(C=C5)C#N)F)N=CC=C4

PF-06445974 (Cat No.: I034488) is a selective dopamine D1 receptor positive allosteric modulator (PAM) developed by Pfizer for neuroscience research. Unlike direct agonists, it enhances the effects of endogenous dopamine at D1 receptors, offering improved specificity and reduced desensitization. PF-06445974 has been investigated for its potential to improve cognition, working memory, and executive function in conditions such as schizophrenia and Parkinson’s disease. Its favorable pharmacological profile makes it a valuable research tool for studying dopaminergic signaling, cognitive enhancement, and neuropsychiatric disorders.

Reference

[1]. Lei Zhang, et al. The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging. J Med Chem. 2017 Oct 26;60(20):8538-8551.
[Content Brief]